$REGN News

Citigroup Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $740

Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg

Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030

REGN Q2 Deep Dive: Pipeline Progress and Product Momentum Drive Outperformance

RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $737

Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $758

Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation

Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $795

Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $750

Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $772

Regeneron Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Regeneron (REGN) Q2 2026 Earnings Call Transcript

Regeneron (REGN) Stock Looks Cheap On Earnings Yet Mixed Elsewhere

Regeneron Pharmaceuticals Inc (REGN) (Q2 2026) Earnings Call Highlights: Record Dupixent Sales ...

Regeneron Pharmaceuticals Q2 Earnings Call Highlights

Regeneron Q2 Earnings Beat, Sales Up on Dupixent & Eylea HD Strength

Why Regeneron (REGN) Is Up 6.7% After Mixed Q2 Results And New Telix Oncology Deal

Regeneron (REGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Regeneron Pharmaceuticals, Inc. (REGN) Q2 2026 Earnings Call Transcript

Regeneron Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation